Indivior Doses First Subject In Phase 2 Study Of INDV-2000 For Opioid Use Disorder, Assessing Safety And Efficacy Over 3 Months In Treatment-Seeking Individuals
Portfolio Pulse from Benzinga Newsdesk
Indivior has initiated a Phase 2 study for INDV-2000, a non-opioid treatment for Opioid Use Disorder. The study will assess the safety and efficacy of INDV-2000 over three months in treatment-seeking individuals.
June 10, 2024 | 6:31 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Indivior has dosed the first subject in a Phase 2 study for INDV-2000, a non-opioid treatment for Opioid Use Disorder. The study aims to measure the safety and efficacy of INDV-2000 over three months.
The initiation of a Phase 2 study for INDV-2000 is a significant milestone for Indivior. Positive results could lead to further clinical trials and potential market approval, which would likely boost the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100